

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF NEW JERSEY

\_\_\_\_\_  
HELSINN HEALTHCARE, S.A. and  
ROCHE PALO ALTO, LLC,

Plaintiffs,

-vs-

DR. REDDY'S LABORATORIES, LTD.,  
DR. REDDY'S LABORATORIES, INC.,  
TEVA PHARMACEUTICALS USA, INC.,  
and TEVA PHARMACEUTICAL  
INDUSTRIES, LTD.

Defendants.

CIVIL ACTION NUMBER:

11-3962

TRIAL

\_\_\_\_\_  
Clarkson S. Fisher United States Courthouse  
402 East State Street  
Trenton, New Jersey 08608  
June 10, 2015

**B E F O R E:**

THE HONORABLE MARY L. COOPER  
UNITED STATES DISTRICT JUDGE

Certified as True and Correct as required by Title 28, U.S.C.,  
Section 753

/S/ Regina A. Berenato-Tell, CCR, CRR, RMR, RPR  
/S/ Carol Farrell, CCR, CRR, RMR, CCP, RPR, RSA

Dr. Reddy's Laboratories, Ltd., et al.  
v.  
Helsinn Healthcare S.A., et al.

1  
2 UNITED STATES DISTRICT COURT  
3 FOR THE DISTRICT OF NEW JERSEY

4 \_\_\_\_\_  
5 HELSINN HEALTHCARE, S.A. and  
6 ROCHE PALO ALTO, LLC,

7 Plaintiffs,

8 -vs-

9 DR. REDDY'S LABORATORIES, LTD.,  
10 DR. REDDY'S LABORATORIES, INC.,  
11 TEVA PHARMACEUTICALS USA, INC.,  
12 and TEVA PHARMACEUTICAL  
13 INDUSTRIES, LTD.

14 Defendants.

15 \_\_\_\_\_  
16 Clarkson S. Fisher United States Courthouse  
17 402 East State Street  
18 Trenton, New Jersey 08608  
19 June 10, 2015

20 **B E F O R E:**

21 THE HONORABLE MARY L. COOPER  
22 UNITED STATES DISTRICT JUDGE

23 Certified as True and Correct as required by Title 28, U.S.C.,  
24 Section 753

25 /S/ Regina A. Berenato-Tell, CCR, CRR, RMR, RPR

/S/ Carol Farrell, CCR, CRR, RMR, CCP, RPR, RSA

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

A P P E A R A N C E S:

PAUL HASTINGS

BY: JOSEPH O'MALLEY, ESQUIRE  
ERIC W. DITTMANN, ESQUIRE  
ANGELA NI, ESQUIRE

SAUL EWING

BY: CHARLES M. LIZZA, ESQUIRE  
Attorneys for the Plaintiffs

BUDD LARNER

BY: STUART D. SENDER, ESQUIRE  
MICHAEL H. IMBACUAN, ESQUIRE  
HUA HOWARD WANG, ESQUIRE  
CONSTANCE S. HUTTNER, ESQUIRE  
KENNETH E. CROWELL, ESQUIRE

ANDREW ALLEN, ESQUIRE  
Attorneys for the Defendant, Dr. Reddy's Laboratories

WINSTON & STRAWN

BY: JOVIAL WONG, ESQUIRE  
GEORGE LOMBARDI, ESQUIRE  
JULIA MANO JOHNSON, ESQUIRE  
BRENDAN F. BARKER, ESQUIRE  
LITE DePALMA, GREENBERG, LLC  
BY: MAYRA V. TARANTINO, ESQUIRE

Attorneys for the Defendant, Teva

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

I N D E X

<u>WITNESS</u>	<u>VOIR DIRE</u>	<u>DIRECT</u>	<u>CROSS</u>	<u>REDIRECT</u>	<u>RECROSS</u>
KEITH CANDIOTTI					
By Mr. Dittman	4	14		266	
By Ms. Huttner			111		276

1 BY MR. DITTMANN:

2 Q. And just to finish and we'll move on from this section,  
3 do you have an opinion as to whether a POSA in 2003 would have  
4 pursued a dose that treated all PONV patients as opposed to  
5 just certain subpopulation groups?

6 A. So, as I was making clear, you'd pick a drug that would  
7 cover as many people as reasonably -- a dose that would cover  
8 as many people as reasonably possible. It would be very  
9 difficult to clinically utilize a drug that was keyed only to  
10 certain subpopulations.

11 Q. Thank you.

12 So, Doctor, we have been talking so far about a PONV  
13 dose. If a POSA was focused on developing a palonosetron drug  
14 product to treat CINV, do you have any opinion as to the dose  
15 they would have pursued?

16 A. So, even during this time period, it was known that  
17 CINV -- chemotherapy is a major toxin, and the doses are  
18 almost always or basically always higher, and anywhere from a  
19 multiple of 2 to 10 perhaps, so if 2 milligrams, using that  
20 dose, is necessary to treat a 70-kilogram person, in  
21 chemotherapy, you would use multiples of that, be it 4 up to  
22 20 milligrams, as it were. That would be a reasonable  
23 assumption, consistent with the other known setrons at the  
24 time.

25 THE COURT: Your answer assumed that the 2 milligrams

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.